Implementation of Telemedicine and Stroke Network in thrombolytic administration: comparison between walk-in and referred patients.
BACKGROUND
The purpose of this study was to evaluate the efficacy and safety of implementation of telemedicine and the Thammasat Stroke Network model in treating acute ischemic stroke patients with intravenous thrombolysis.


METHODS
Telemedicine (telephone consultation and tele-radiology) has been used in acute ischemic stroke management since June, 2007. The Thammasat Stroke Network (TSN) was effectively organized in March, 2008. Thammasat Hospital served as a "hub" hospital, with 25 "spoke" hospitals in the TSN. The main outcome measures included favorable outcome of the patients treated with intravenous tissue plasminogen activator (tPA) at 3 months and symptomatic intracerebral hemorrhage by comparison between walk-in patients and the patients who were referred by the TSN.


RESULTS
There were 14 patients (14 out of 170 acute ischemic stroke patients, 8%) and 110 patients (110 out of 406 patients, 27%) receiving tPA, before and after implementation of TSN, respectively. Walk-in patients (66 patients) had significant shorter onset-to-treatment duration as compared with referred patients (58 patients) (130 vs. 170 min, P < 0.0001). However, there was no significant difference in favorable outcome (48 vs. 42%, P = 0.538) and rate of symptomatic intracerebral hemorrhage (3 vs. 2%, P = 0.637).


CONCLUSIONS
Implementation of telemedicine and TSN markedly increased tPA administrations, without compromising favorable and safety outcomes.
Dharmasaroja
Pornpatr A
PA
Division of Neurology, Faculty of Medicine, Thammasat University, Pathumthani, Thailand. pornpatr1@hotmail.com
Muengtaweepongsa
Sombat
S
Kommarkg
Urai
U
D000368:Aged; D002545:Brain Ischemia / Q000150:complications; D002543:Cerebral Hemorrhage / Q000139:chemically induced / Q000453:epidemiology; D003195:Computer Communication Networks; D005260:Female; D005343:Fibrinolytic Agents / Q000008:administration & dosage*; D006801:Humans; D015994:Incidence; D007275:Injections, Intravenous; D008297:Male; D008875:Middle Aged; D012017:Referral and Consultation; D020521:Stroke / Q000188:drug therapy* / Q000209:etiology; D017216:Telemedicine; D013997:Time Factors; D010959:Tissue Plasminogen Activator / Q000008:administration & dosage* / Q000009:adverse effects; D016896:Treatment Outcome
D005343:Fibrinolytic Agents; D010959:Tissue Plasminogen Activator
Int J Stroke. 2006 Nov;1(4):201-7
18706017
Stroke. 2003 Mar;34(3):725-8
12624298
Stroke. 2005 Feb;36(2):287-91
15625294
Lancet Neurol. 2008 Sep;7(9):787-95
18676180
Stroke. 2004 Jul;35(7):1763-8
15166386
N Engl J Med. 1995 Dec 14;333(24):1581-7
7477192
Stroke. 2009 Jul;40(7):2616-34
19423852
Clin Neurol Neurosurg. 2006 Sep;108(6):549-52
16289309
Clin Neurol Neurosurg. 2008 May;110(5):451-4
18353532
Lancet Neurol. 2006 Sep;5(9):742-8
16914402
Neurology. 2007 Aug 28;69(9):898-903
17724293
J Stroke Cerebrovasc Dis. 2008 Mar-Apr;17(2):82-5
18346650
Cerebrovasc Dis. 2009;27 Suppl 4:1-8
19546535
Stroke. 2005 Sep;36(9):2018-20
16051892
Lancet. 1998 Oct 17;352(9136):1245-51
9788453
Stroke. 2006 Jul;37(7):1822-7
16763192
Neurocrit Care. 2005;3(1):27-32
16159092
N Engl J Med. 2008 Sep 25;359(13):1317-29
18815396